Skip to content

International LIT Symposium 2024

More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg.

Article Details

  • Date Published

    July 2, 2024

International LIT Symposium in Herzogsaal

The symposium covered all aspects of new cellular therapies for to-date incurable diseases with presentations from outstanding experts creating a think tank environment that provided cutting edge insights into the latest developments in the field and ample time for discussions of novel ideas and concepts.

In the past years, synthetic immunology has made great progress – not only in regard to introducing novel reprogramming strategies into human immune cells to target them against tumors, but also for the treatment of inflammatory and autoimmune diseases.

Yet, there are still major hurdles to be overcome on the way to efficient, safe and inexpensive immune cell products and medications. These include for example the development of truly cancer specific cellular therapies, the implementation of further capacities into human T cells, and the rising potential of artificial intelligence in synthetic immunology.

Scientists of the Leibniz Institute for Immunotherapy (LIT) contribute to the global progress in this dynamic field of medicine with cutting-edge innovations at the forefront of research worldwide and novel treatment concepts for diseases such as cancer, autoimmune diseases, and chronic inflammation.

Group picture in front of Regensburg Cathedral

Leading experts worldwide who presented their latest research findings at the symposium were – in alphabetical order:

  • Hinrich Abken (Leibniz Institute for Immunotherapy, Regensburg, Germany)
  • Franziska Blaeschke (German Cancer Research Center and Hopp-Kindertumorzentrum Heidelberg, Germany)
  • Markus Feuerer (Leibniz Institute for Immunotherapy, Regensburg, Germany)
  • Luca Gattinoni (Leibniz Institute for Immunotherapy, Regensburg, Germany )
  • Alena Gros Vidal (Vall d´Hebron Institute of Oncology, Barcelona, Spain)
  • John Haanen (The Netherlands Cancer Institute, Amsterdam, Netherlands)
  • Michael Jensen (BrainChild Bio, Inc. and University of Washington School of Medicine (retired), Seattle, USA)
  • Markus Jeschek (University of Regensburg, Germany)
  • Carl June (University of Pennsylvania, Philadelphia, USA)
  • Christopher Klebanoff (Memorial Sloan Kettering Cancer Center, New York, USA)
  • Megan Levings (The University of British Columbia and BC Children’s Hospital Research Institute, Vancouver, Canada)
  • John Maher (King´s College London, UK)
  • Jens Meiler (Leipzig University, Germany)
  • Marcela V. Maus (Harvard Medical School and Mass General Cancer Center, Boston, USA)
  • Cristina Puig Saus (University of California, Los Angeles, USA)
  • Shimon Sakaguchi (Osaka University, Osaka, Japan)
  • Kilian Schober (Universitätsklinikum Erlangen, Germany)
  • Velia Siciliano (Istituto Italiano di Tecnologia, Genova, Italy)
  • Naomi Taylor (National Cancer Institute Center for Cancer Research, Bethesda, USA)
  • Fabian Theis (Helmholtz Munich, Technical University of Munich, Germany)

Poster session in Salzstadel

About the Leibniz Institute for Immunotherapy (LIT)
The Leibniz Institute for Immunotherapy (LIT) is an institute within the Leibniz Association located in Regensburg, Germany. Our mission is to develop innovative therapies for the treatment of cancer, autoimmunity, and chronic inflammation. By reprogramming immune cells through synthetic and pharmacological strategies, we build cells that save lives.